Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19.
Agatston score
Atherosclerosis
COVID-19
Calcium score
Coronary artery calcifications
Coronary artery disease
In-hospital mortality
Journal
Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
19
01
2021
revised:
24
03
2021
accepted:
31
03
2021
pubmed:
23
4
2021
medline:
9
7
2021
entrez:
22
4
2021
Statut:
ppublish
Résumé
The potential impact of coronary atherosclerosis, as detected by coronary artery calcium, on clinical outcomes in COVID-19 patients remains unsettled. We aimed to evaluate the prognostic impact of clinical and subclinical coronary artery disease (CAD), as assessed by coronary artery calcium score (CAC), in a large, unselected population of hospitalized COVID-19 patients undergoing non-gated chest computed tomography (CT) for clinical practice. SARS-CoV 2 positive patients from the multicenter (16 Italian hospitals), retrospective observational SCORE COVID-19 (calcium score for COVID-19 Risk Evaluation) registry were stratified in three groups: (a) "clinical CAD" (prior revascularization history), (b) "subclinical CAD" (CAC >0), (c) "No CAD" (CAC = 0). Primary endpoint was in-hospital mortality and the secondary endpoint was a composite of myocardial infarction and cerebrovascular accident (MI/CVA). Amongst 1625 patients (male 67.2%, median age 69 [interquartile range 58-77] years), 31%, 57.8% and 11.1% had no, subclinical and clinical CAD, respectively. Increasing rates of in-hospital mortality (11.3% vs. 27.3% vs. 39.8%, p < 0.001) and MI/CVA events (2.3% vs. 3.8% vs. 11.9%, p < 0.001) were observed for patients with no CAD vs. subclinical CAD vs clinical CAD, respectively. The association with in-hospital mortality was independent of in-study outcome predictors (age, peripheral artery disease, active cancer, hemoglobin, C-reactive protein, LDH, aerated lung volume): subclinical CAD vs. No CAD: adjusted hazard ratio (adj-HR) 2.86 (95% confidence interval [CI] 1.14-7.17, p=0.025); clinical CAD vs. No CAD: adj-HR 3.74 (95% CI 1.21-11.60, p=0.022). Among patients with subclinical CAD, increasing CAC burden was associated with higher rates of in-hospital mortality (20.5% vs. 27.9% vs. 38.7% for patients with CAC score thresholds≤100, 101-400 and > 400, respectively, p < 0.001). The adj-HR per 50 points increase in CAC score 1.007 (95%CI 1.001-1.013, p=0.016). Cardiovascular risk factors were not independent predictors of in-hospital mortality when CAD presence and extent were taken into account. The presence and extent of CAD are associated with in-hospital mortality and MI/CVA among hospitalized patients with COVID-19 disease and they appear to be a better prognostic gauge as compared to a clinical cardiovascular risk assessment.
Sections du résumé
BACKGROUND AND AIMS
The potential impact of coronary atherosclerosis, as detected by coronary artery calcium, on clinical outcomes in COVID-19 patients remains unsettled. We aimed to evaluate the prognostic impact of clinical and subclinical coronary artery disease (CAD), as assessed by coronary artery calcium score (CAC), in a large, unselected population of hospitalized COVID-19 patients undergoing non-gated chest computed tomography (CT) for clinical practice.
METHODS
SARS-CoV 2 positive patients from the multicenter (16 Italian hospitals), retrospective observational SCORE COVID-19 (calcium score for COVID-19 Risk Evaluation) registry were stratified in three groups: (a) "clinical CAD" (prior revascularization history), (b) "subclinical CAD" (CAC >0), (c) "No CAD" (CAC = 0). Primary endpoint was in-hospital mortality and the secondary endpoint was a composite of myocardial infarction and cerebrovascular accident (MI/CVA).
RESULTS
Amongst 1625 patients (male 67.2%, median age 69 [interquartile range 58-77] years), 31%, 57.8% and 11.1% had no, subclinical and clinical CAD, respectively. Increasing rates of in-hospital mortality (11.3% vs. 27.3% vs. 39.8%, p < 0.001) and MI/CVA events (2.3% vs. 3.8% vs. 11.9%, p < 0.001) were observed for patients with no CAD vs. subclinical CAD vs clinical CAD, respectively. The association with in-hospital mortality was independent of in-study outcome predictors (age, peripheral artery disease, active cancer, hemoglobin, C-reactive protein, LDH, aerated lung volume): subclinical CAD vs. No CAD: adjusted hazard ratio (adj-HR) 2.86 (95% confidence interval [CI] 1.14-7.17, p=0.025); clinical CAD vs. No CAD: adj-HR 3.74 (95% CI 1.21-11.60, p=0.022). Among patients with subclinical CAD, increasing CAC burden was associated with higher rates of in-hospital mortality (20.5% vs. 27.9% vs. 38.7% for patients with CAC score thresholds≤100, 101-400 and > 400, respectively, p < 0.001). The adj-HR per 50 points increase in CAC score 1.007 (95%CI 1.001-1.013, p=0.016). Cardiovascular risk factors were not independent predictors of in-hospital mortality when CAD presence and extent were taken into account.
CONCLUSIONS
The presence and extent of CAD are associated with in-hospital mortality and MI/CVA among hospitalized patients with COVID-19 disease and they appear to be a better prognostic gauge as compared to a clinical cardiovascular risk assessment.
Identifiants
pubmed: 33883086
pii: S0021-9150(21)00165-9
doi: 10.1016/j.atherosclerosis.2021.03.041
pmc: PMC8025539
pii:
doi:
Substances chimiques
Calcium
SY7Q814VUP
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
136-143Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Cardiovasc Res. 2020 Dec 1;116(14):2177-2184
pubmed: 32750108
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
Age Ageing. 2021 May 5;50(3):608-616
pubmed: 33951151
Eur Heart J Cardiovasc Imaging. 2020 Sep 1;21(9):1055-1056
pubmed: 32671381
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910
JACC Cardiovasc Imaging. 2020 Nov;13(11):2468-2470
pubmed: 33153535
Eur Heart J. 2018 Jul 1;39(25):2401-2408
pubmed: 29688297
Circulation. 2017 Nov 21;136(21):1993-2005
pubmed: 28847895
Coron Artery Dis. 2021 Aug 1;32(5):367-371
pubmed: 32732512
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Arch Gerontol Geriatr. 2021 Mar-Apr;93:104324
pubmed: 33352430
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Am Coll Cardiol. 2020 Sep 8;76(10):1168-1176
pubmed: 32679155
J Am Coll Cardiol. 2018 Jul 24;72(4):434-447
pubmed: 30025580
JACC Cardiovasc Imaging. 2020 Dec;13(12):2698
pubmed: 33303104
J Am Coll Cardiol. 2019 Sep 24;74(12):1608-1617
pubmed: 31537271
Eur Heart J Cardiovasc Imaging. 2020 May 1;21(5):479-488
pubmed: 32065624
Circ Cardiovasc Imaging. 2013 Jul;6(4):514-21
pubmed: 23756678